Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises iBinder Group in connection with the acquisition of Avima AB
Mandate

Vinge advises iBinder Group in connection with the acquisition of Avima AB

October 07, 2024 M&A Intellectual Property Corporate Commercial Employment and Benefits Corporate Tax IT, Telecommunications and Outsourcing

Avima AB is a Swedish specialist in project and information management, with expertise in complex projects within construction, real estate and infrastructure.

iBinder Group offers digital information management services for the construction and real estate industry. iBinder Group was founded in 2005 and the company helps clients increase productivity, reduce environmental impact and comply with laws and regulations in construction projects and real estate management.

Vinge’s team consisted of Johanna Wiberg, Johanna Hamrefält (Project Manager), Johan Gavelin (IP), Elis Allmark (Commercial/IT), Emelie Svanberg and Victor Ericsson (Tax), Jonna Skog (Employment) and Amelia Rihs (M&A).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025